Establishing the China–UK Cancer Prevention and Control Alliance
Uloženo v:
| Vydáno v: | Lancet Oncology vol. 26, no. 9 (Sep 2025), p. 1132-1135 |
|---|---|
| Hlavní autor: | |
| Další autoři: | , , , , , , , , , , , , , , , , , , , , , |
| Vydáno: |
Elsevier Limited
|
| Témata: | |
| On-line přístup: | Citation/Abstract Full Text Full Text - PDF |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3245554968 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1470-2045 | ||
| 022 | |a 1474-5488 | ||
| 024 | 7 | |a 10.1016/S1470-2045(25)00437-1 |2 doi | |
| 035 | |a 3245554968 | ||
| 045 | 2 | |b d20250901 |b d20250930 | |
| 084 | |a 95210 |2 nlm | ||
| 100 | 1 | |a Ma, Jun |u Sun Yat-Sen University, Guangzhou, China | |
| 245 | 1 | |a Establishing the China–UK Cancer Prevention and Control Alliance | |
| 260 | |b Elsevier Limited |c Sep 2025 | ||
| 513 | |a Commentary | ||
| 520 | 3 | |a Given China's emergent position as one of the global leaders in artificial intelligence, a tremendous opportunity exists to apply it across the spectrum of cancer control, improving patient care by enhancing detection, survival prediction, and treatment efficacy. Both countries should provide governmental and financial support to extend collaboration between top UK and Chinese medical schools, exemplified by the successful collaboration between the University of Oxford and Sichuan University Joint Centre for Gastrointestinal Cancer in 2020, that has developed a model of one team based across two sites, with an operating and governance system that drives the exchange of ideas, researchers, and clinicians. 4 In terms of governance, we propose a steering group, co-chaired by a senior Chinese and UK oncologist, supported by other leaders in the field from both nations, who would be asked to co-chair working groups, which would address various topics (ie, prevention, early detection and screening, multidisciplinary cancer treatment, research, palliative and survivor care, and governance and systems, including health workforce and information systems) and provide a report capturing current practice and evolved models of care, which can be used as a blueprint or manual for other countries with nascent cancer systems. CS received funding from the Francis Crick Institute that receives its core funding from Cancer Research UK (CC2041), the UK Medical Research Council (CC2041), the Wellcome Trust (CC2041), and the Royal Society (RSRP\R\210001, paid to institution); grants from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Invitae, Ono Pharmaceuticals, Personalis, and Pfizer; consulting fees from Bicycle Therapeutics, Genentech, Medicxi, Novartis, Relay Therapeutics, China Innovation Centre of Roche (CICoR), SAGA Diagnostics, and Sarah Canon Research Institute; honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Illumina, GlaxoSmithKline, Merck Sharp & Dohme, Roche–Ventana, Pfizer, and AstraZeneca; is on a scientific advisory board for GRAIL; is the Chief Clinician for Cancer Research UK; is the co-founder of Achilles Therapeutics; has patents with; has stock options for Epic Biosciences, Relay Therapeutics, GRAIL, Bicycle Therapeutics, and Achilles Therapeutics; is the Chief Investigator of the MeRmaiD 1 and 2 clinical trials for AstraZeneca; and is the Co-Chief Investigator of the GRAIL–NHS Galleri Trial for GRAIL. TM received grants from AstraZeneca, Bristol Myers Squibb, G1 Therapeutics, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche, SFJ, Takeda, and XCovery; consulting fees from AbbVie, ACEA Pharma, Adagene, Alentis Therapeutics, Alpha Biopharma, Amgen, Amoy Diagnostics, AnHeart Therapeutics, AVEO Pharmaceuticals, Bayer, BeiGene, BerGenBio ASA, Berry Oncology, Boehringer Ingelheim, Blueprint Medicines Corporation, Bridge Bio, Bristol Myers Squibb, Bowtie Life Insurance Company, Bridge Biotherapeutics, Covidien LP, C4 Therapeutics, Cirina, CStone Pharmaceuticals, Curio Science, D3 Bio, Da Volterra, Daiichi Sankyo, Eisai, Elevation Oncology, Erasca, F Hoffmann–La Roche/Genentech, Fishawack Facilitate, G1 Therapeutics, geneDecode, Gilead Sciences, GLG's Healthcare, Gritstone Oncology, Guardant Health, Hengrui Therapeutics, HiberCell, HutchMed, Ignyta, Illumina Imagene AI, Incyte, Inivata, InxMed, IQVIA, Janssen, Lakeshore Biotech, Lilly, Lunit USA, Loxo-Oncology, Lucence Health, Medscape/WebMD, Medtronic, Merck Serono, Merck Sharp & Dohme, Mirati Therapeutics, MiRXES, MoreHealth, Novartis, Novocure, Ningbo NewBay Technology Development, Omega Therapeutics, OrigiMed, OSE Immunotherapeutics, PeerVoice, Phanes Therapeutics, Pfizer, PrIME Oncology, Prenetics Global, Puma Biotechnology, Qiming Development, Regen Medtech Holdings, Regeneron Pharmaceuticals, Roche Pharmaceuticals/Diagnostics/Foundation One, Sanofi Aventis, Schrödinger, Seagen International, SFJ, Simcere of America, Synergy Research, Summit Therapeutics Sub, Takeda Pharmaceuticals, Tigermed, Vertex Pharmaceuticals, Virtus Medical Group, XENCOR, and Yuhan Corporation; honoraria from ACEA Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, AstraZeneca (before Jan 1, 2019), BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Daz Group, Fishawack Facilitate, InMed Medical Communication, Janssen Pharmaceutica NV, Jiahui Holdings, LiangYiHui Healthcare, Lilly, Lucence Health, MD Health Brazil, Medscape, Merck Pharmaceuticals, Merck Sharp & Dohme, MiRXES, Novartis, OrigiMed, P Permanyer SL, PeerVoice, Physicians’ Education Resource, Pfizer, PrIME Oncology, Research to Practice, Roche Pharmaceuticals/Diagnostics/Foundation One, Sanofi Aventis, Shanghai BeBirds Translation & Consulting, Taiho Pharmaceutical, Takeda Oncology, and Touch Independent Medical Education; support for attending meetings or travel from Novartis, Roche, Pfizer (personal and to institution), AstraZeneca, Daiichi Sankyo, Takeda, MiRXES, AbbVie, Zai Lab, Liangyihui, Lu Ye Pharma, Beigene, and Merck Sharp & Dohme; participated on a data safety monitoring board or advisory board for AbbVie, ACEA Pharma, Amgen, AstraZeneca, Alentis Therapeutics AG, BerGenBio ASA, Berry Oncology, Blueprint Medicines Corporation, Boehringer Ingelheim, Bowtie Life Insurance, Bristol Myers Squibb, C4 Therapeutics, Covidien LP, CStone Pharmaceuticals, Curio Science, D3 Bio Ltd, Daiichi Sankyo, Eisai, Erasca, Fishawack Facilitate, G1 Therapeutics, Gilead Sciences, Gritstone Oncology, Guardant Health, geneDecode (unpaid), Hengrui Therapeutics, HutchMed, Ignyta, Incyte, Imagene AI, Inivata, IQVIA, Janssen, Lakeshore Biotech, Lilly, Loxo-Oncology, Lunit, Merck Serono, Merck Sharp & Dohme, Mirati Therapeutics, MiRXES, Novartis, OrigiMed, Phanes Therapeutics, Pfizer, Prenetics Global, Puma Biotechnology, Roche/Genentech, Regeneron Pharmaceuticals, Sanofi Aventis, SFJ, Simcere of America, Simcere Zaiming, Takeda, Vertex Pharmaceuticals, Virtus Medical Group, XENCOR, and Yuhan Corporation; has a leadership or fiduciary role with EPOCH BIOSCIENCES (unpaid), AstraZeneca, HutchMed, Aurora, and Insighta; and has stock or stock options with AstraZeneca, Aurora Tele-Oncology, Biolidics, HutchMed, Prenetics Global, D3 Bio, Lunit, Bowtie Life Insurance, Lakeshore Biotech, Loxo-Oncology, Virtus Medical Group, Yinson Capital, Phanes Therapeutics, Insighta, Alentis Therapeutics AG, and EPOCH BIOSCIENCES. | |
| 610 | 4 | |a Vertex Pharmaceuticals Inc Cancer Research UK Sanofi-Aventis SA AstraZeneca AbbVie Inc Bristol-Myers Squibb Co Daiichi Sankyo Co Ltd BerGenBio ASA Gilead Sciences Inc Pfizer Inc Regeneron Pharmaceuticals Inc Genentech Inc Amgen Inc Merck Sharp & Dohme Mirati Therapeutics Inc | |
| 651 | 4 | |a United Kingdom--UK | |
| 651 | 4 | |a China | |
| 653 | |a Clinical trials | ||
| 653 | |a Artificial intelligence | ||
| 653 | |a Collaboration | ||
| 653 | |a Funding | ||
| 653 | |a Information systems | ||
| 653 | |a Biotechnology | ||
| 653 | |a Oncology | ||
| 653 | |a Patents | ||
| 653 | |a Leadership | ||
| 653 | |a Medical research | ||
| 653 | |a Disease prevention | ||
| 653 | |a Cancer research | ||
| 653 | |a Life insurance | ||
| 653 | |a Drug development | ||
| 653 | |a Pharmacology | ||
| 653 | |a Health care | ||
| 653 | |a Medical innovations | ||
| 653 | |a Councils | ||
| 653 | |a Cooperation | ||
| 653 | |a Pharmaceuticals | ||
| 653 | |a Biomarkers | ||
| 653 | |a Stock options | ||
| 653 | |a Biopharmaceuticals | ||
| 653 | |a Education | ||
| 653 | |a Cancer therapies | ||
| 700 | 1 | |a Kerr, David |u University of Oxford, Oxford, OX1 2JD, UK | |
| 700 | 1 | |a Shi, Yuankai |u Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China | |
| 700 | 1 | |a Swanton, Charles |u The Francis Crick Institute, London, UK | |
| 700 | 1 | |a Mok, Tony |u Chinese University of Hong Kong, Ma Lui Shui, Hong Kong Special Administrative Region, China | |
| 700 | 1 | |a Fitzgerald, Rebecca |u University of Cambridge, Cambridge, UK | |
| 700 | 1 | |a Xu, Rui-Hua |u Sun Yat-Sen University, Guangzhou, China | |
| 700 | 1 | |a Cowan, Richard |u Christie Hospital NHS Trust, Manchester, UK | |
| 700 | 1 | |a Lin, Rong |u Union Hospital, Tongji Medical College, Tongji, China | |
| 700 | 1 | |a Lawler, Mark |u Chinese University of Hong Kong, Ma Lui Shui, Hong Kong Special Administrative Region, China | |
| 700 | 1 | |a Teng, Gao-Jun |u Southeast University, Jiangsu, China | |
| 700 | 1 | |a Eisen, Tim |u University of Cambridge, Cambridge, UK | |
| 700 | 1 | |a Li, Molly |u Queen's University Belfast, Belfast, Northern Ireland | |
| 700 | 1 | |a Kyrgiou, Maria |u Imperial College London, London, UK | |
| 700 | 1 | |a Ko, Fanny Wai San |u Chinese University of Hong Kong, Ma Lui Shui, Hong Kong Special Administrative Region, China | |
| 700 | 1 | |a Middleton, Mark |u University of Oxford, Oxford, OX1 2JD, UK | |
| 700 | 1 | |a Xu, Binghe |u Peking Union Medical College Hospital, Beijing, China | |
| 700 | 1 | |a Aboyage, Eric |u Imperial College London, London, UK | |
| 700 | 1 | |a Xiao, Dan |u China–Japan Friendship Hospital, Beijing, China | |
| 700 | 1 | |a Wu, Yi-Long |u Chinese University of Hong Kong, Ma Lui Shui, Hong Kong Special Administrative Region, China | |
| 700 | 1 | |a Puroshotham, Arnie |u King's College London, London, UK | |
| 700 | 1 | |a Yang, Li |u Sichuan University West China Hospital, Sichuan, China | |
| 700 | 1 | |a Fan, Daiming |u Xijing Hospital, Shaanxi, China | |
| 773 | 0 | |t Lancet Oncology |g vol. 26, no. 9 (Sep 2025), p. 1132-1135 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3245554968/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3245554968/fulltext/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3245554968/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |